CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection

European Journal of Immunology

Volumn 42, Issue 4, 2012, Pages 870-879

  Beamer, Gillian L ^a   Cyktor, Joshua ^a   Flaherty, David K ^b   Stromberg, Paul C ^a   Carruthers, Bridget ^a   Turner, Joanne ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antigen 85; CBA J; Murine; Tuberculosis; Vaccination

Indexed keywords

AG85 ANTIGEN; BCG VACCINE; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; RECOMBINANT AG85 ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; MOUSE; NONHUMAN; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MICE; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS; VACCINATION;

EID: 84860244273     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201142054     Document Type: Article

References (46)

1. World Health Organisation. WHO fact file: 10 facts about tuberculosis 2009.
2. Hunter, R., Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis 2011. 91: 497-509.
3. Shende, N., Gutpa, S., Upadhye, V., Kumar, S. and Harinth, B., Isolation and analysis of circulating tuberculous antigens in Mycobacterium tuberculosis. Indian J. Tuberc. 2007. 54: 125-129.
4. Huygen, K., Van Vooren, J., Turneer, M., Bosmans, R., Dierckx, P. and De Bruyn, J., Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand. J. Immunol. 1988. 27: 187-194.
5. Demissie, A., Ravn, P., Olobo, J., Doherty, T. M., Eguale, T., Geletu, M. et al., T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infect. Immun. 1999. 67: 5967-5971.
6. Kamath, A. B., Alt, J. M., Debbabi, H., Taylor, C. and Behar, S. M., The major histocompatibility haplotype affects T-cell recognition of mycobacterial antigens but not resistance to Mycobacterium tuberculosis in C3H mice. Infect. Immun. 2004. 72: 6790-6798.
7. Beamer, G., Cyktor, J., Carruthers, B. and Turner, J., H-2 alleles contribute to Antigen 85-specific interferon-gamma responses during Mycobacterium tuberculosis infection. Cell. Immunol. 2011. 271: 53-61.
8. Whelan, K. T., Pathan, A. A., Sander, C. R., Fletcher, H. A., Poulton, I., Alder, N. C., Hill, A. V. S. et al., Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 2009. 4: e5934.
9. Medina, E. and North, R. J., Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunol. 1998. 93: 270-274.
10. Turner, J., Gonzalez-Juarrero, M., Saunders, B. M., Brooks, J. V., Marietta, P., Ellis, D. L., Frank, A. A. et al., Immunological basis for reactivation of tuberculosis in mice. Infect. Immun. 2001. 69: 3264-3270.
11. Beamer, G. L., Flaherty, D. K., Vesosky, B. and Turner, J., Peripheral blood interferon-{gamma} release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin. Vacc. Immunol. 2008. 15: 474-483.
12. Rogerson, B. J., Jung, Y.-J., LaCourse, R., Ryan, L., Enright, N. and North, R. J., Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology 2006. 118: 195-201.
13. Dietrich, J., Aagaard, C., Leah, R., Olsen, A. W., Stryhn, A., Doherty, T. M. and Andersen, P., Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 2005. 174: 6332-6339.
14. Romano, M., Roupie, V., Wang, X., Denis, M., Jurion, F., Adnet, P.-Y., Laali, R. et al., Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor Pst-3. Immunology 2006. 118: 321-332.
15. Medina, E. and North, R., Genetically susceptible mice remain proportionally more susceptible to tuberculosis after vaccination. Immunology 1999. 96: 16-21.
16. Dannenberg, A. M., Jr., Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin. Microbiol. Rev. 2010. 23: 781-794.
17. Wiker, H. G. and Harboe, M., The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol. Mol. Biol. Rev. 1992. 56: 648-661.
18. van Dissel, J. T., Arend, S. M., Prins, C., Bang, P., Tingskov, P. N., Lingnau, K., Nouta, J. et al., Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T-cell responses in naïve human volunteers. Vaccine 2010. 28: 3571-3581.
19. D'Souza, S., Rosseels, V., Romano, M., Tanghe, A., Denis, O., Jurion, F., Castiglione, N. et al., Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 2003. 71: 483-493.
20. Lozes, E., Huygen, K., Content, J., Denis, O., Montgomery, D. L., Yawman, A. M., Vandenbussche, P. et al., Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 1997. 15: 830-833.
21. Ulmer, J. B., Liu, M. A., Montgomery, D. L., Yawman, A. M., Randall Deck, R., DeWitt, C. M., Content, J. et al., Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997. 15: 792-794.
22. Duffy, D., Dawoodji, A., Agger, E., Andersen, P., Westermann, J. and Bell, E., Immunological memory transferred with CD4 T cells specific for tuberculosis Ag85B-TB10.4: persisting antigen enhances protection. PLoS One 2009. 4: e8272.
23. Bennekov, T., Dietrich, J., Rosenkrands, I., Stryhn, A., Doherty, T. â. M. and Andersen, P., Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur. J. Immunol. 2006. 36: 3346-3355.
24. Dietrich, J., Andersen, C., Rappuoli, R., Doherty, T. M., Jensen, C. G. and Andersen, P., Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 2006. 177: 6353-6360.
25. Giri, P. K., Verma, I. and Khuller, G. K., Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol. Med. Microbiol. 2006. 47: 233-241.
26. Malowany, J., McCormick, S., Santosuosso, M., Xizhong, Z., Aoki, N., Ngai, P., Wang, J., et al., Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts. Mol. Ther. 2006. 13: 766-774.
27. Langermans, J. A. M., Doherty, T. M., Vervenne, R. A. W., Laan, T. V. d., Lyashchenko, K., Greenwald, R., Agger, E. M. et al., Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005. 23: 2740-2750.
28. Horwitz, M., Harth, G., Dillon, B. and Maslesa-Galic, S., Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory product induce greater protective immunity in a highly susceptible animal model. Proc. Nat. Acad. Sci. USA 2000. 97: 13853-13858.
29. McShane, H., Pathan, A. A., Sander, C. R., Goonetilleke, N. P., Fletcher, H. A. and Hill, A. V. S., Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 2005. 85: 47-52.
30. González-Juarrero, M., Turner, J., Basaraba, R. J., Belisle, J. T. and Orme, I. M., Florid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cell. Imunol. 2002. 220: 13-19.
31. Taylor, J., Turner, O., Basaraba, R., Belisle, J., Huygen, K. and Orme, I., Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 2003. 71: 2192-2198.
32. D'Souza, S., Denis, O., Scorza, T., Nzabintwali, F., Verschueren, H. and Huygen, K., CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A. Eur. J. Immunol. 2000. 30: 2455-2499.
33. Turner, J., Rhoades, E., Keen, M., Belisle, J., Frank, A. and Orme, I., Effective pre-exposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect. Immun. 2000. 68: 1706-1709.
34. Beamer, G. L., Flaherty, D. K., Assogba, B. D., Stromberg, P., Gonzalez-Juarrero, M., de Waal Malefyt, R., Vesosky, B. et al., Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J. Immunol. 2008. 181: 5545-5550.
35. Andersen, P., Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 1994. 62: 2536-2544.
36. Hubbard, R. D., Flory, C. M. and Collins, F. M., Memory T cell-mediated resistance to Mycobacterium tuberculosis infection in innately susceptible and resistant mice. Infect. Immun. 1991. 59: 2012-2016.
37. Buccheri, S., Reljic, R., Caccamo, N., Meraviglia, S., Ivanyi, J., Salerno, A. and Dieli, F., Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. Tuberculosis 2009. 89: 91-94.
38. Cynamon, M., Sklaney, M. R. and Shoen, C., Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J. Antimicrob. Chemother. 2007. 60: 429-432.
39. Cardona, P.-J., Amat, I., Gordillo, S., Arcos, V., Guirado, E., Díaz, J., Vilaplana, C. et al., Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005. 23: 1393-1398.
40. Bachmanov, A. A., Reed, D. R., Beauchamp, G. K. and Tordoff, M. G., Food Intake, Water Intake, and Drinking Spout Side Preference of 28 Mouse Strains Behavior Genetics. Springer, the Netherlands, 2002. 32: pp. 435-443.
41. Biancifiori, C. and Severi, L., The relation of isoniazid (INH) and allied compounds to carcinogenesis in some species of small laboratory animals: a review. Br. J. Cancer 1966. 20: 528-538.
42. Grosset, J. and Leventis, S., Adverse effects of rifampin. Rev. Infect. Dis. 1983. 3(Suppl): S440-S450.
43. Vesosky, B., Flaherty, D. K., Rottinghaus, E. K., Beamer, G. L. and Turner, J., Age dependent increase in early resistance of mice to Mycobacterium tuberculosis is associated with an increase in CD8 T cells that are capable of antigen independent IFN-gamma production. Expt. Gerontol. 2006. 41: 1185-1194.
44. Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R. and Allison, J., P., CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Nat. Acad. Sci. USA 1998. 95: 10067-10071.
45. Vesosky, B., Rottinghaus, E. K., Stromberg, P., Turner, J. and Beamer, G., CCL5 participates in early protection against Mycobacterium tuberculosis. J. Leuk. Biol. 2010. 87: 1153-1165.
46. Gonzalez-Juarrero, M., Shim, T. S., Kipnis, A., Junqueira-Kipnis, A. P. and Orme, I. M., Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J. Immunol. 2003. 171: 3128-3135.